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    Huntington disease is an autosomal dominant neurodegenerative disorder. The abnormally 
long CAG-repeats in the huntingtin gene that encode an expanded polyglutamine stretch which 
promotes self-assemble of huntingtin into different aggregation species that are disease related. 
Huntingtin intimately interacts with a variety of lipid membranes. Lipid composition is altered in 
HD, especially cholesterol content. Here we investigate how cholesterol content modulates the 
interaction between huntingtin and lipid membranes. TBLE/PDA binding assay is performed to 
test the binding affinity of huntingtin with lipid bilayers containing different amount of cholesterol. 
As the cholesterol content increases, the extent of huntingtin binding to lipid bilayers decreases. 
Also, atomic force microscopy (AFM) is used to directly monitor the formation of aggregates on 
supported lipid bilayers containing exogenously added cholesterol. Morphological and mechanical 
changes in the bilayers exposed to huntingtin are observed by the presence of cholesterol. On pure 
TBLE, globular aggregates are formed and grainy in appearance. Most of the bilayers are disrupted. 
In contrast, lipid bilayers enriched in different amount of cholesterol facilitate the formation of 
plateau-like aggregates with a smooth appearance. With the increase of cholesterol content in lipid 
bilayers, the percentage of the surface disrupted by the protein aggregation decreases. In sum, the 
presence and amount of cholesterol in lipid bilayers modulates the huntingtin binding and 
aggregation on lipid membranes. 
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A common feature of neurodegenerative diseases such as Alzheimer’s disease 
(AD), Parkinson’s disease (PD), and Huntington’s disease (HD), is the formation of 
protein aggregates that deposit in tissues or cellular compartments [1]. Non-native 
conformation of specific proteins promotes their self-assembly into insoluble 
aggregates. These diseases related aggregates are comprised of extend, ß-sheet rich 
fibrils, referred to as amyloid, and thus these diseases are referred to as amyloid disease. 
Amyloid formation typically occurs via the nucleation-growth mechanism, which is 
comprised of a lag phase and a growth phase [1-3]. However, the assembly process of 
aggregates can adopt a myriad of complex aggregation pathways (Figure 1). A variety 
of aggregate species (e.g. oligomers, amorphous aggregates, protofibrils, and fibrils) 
can be observed along the aggregation pathway.  
 
 
Figure 1. A generic aggregation scheme for amyloid-forming proteins[4]. Proteins typically 
fold into a low-energy native conformation, but sometimes a protein gets trapped in a local energy 
minimum associated with a misfolded conformation. This leads directly to protein aggregation 
into amyloid fibrils. The aggregation proceeds through several metastable intermediates 




Environment can influence the formation of protein aggregates, and one such 
environmental factor is the presence of surfaces. Conformational changes can be 
induced when proteins encounter surfaces [5]. Different aggregate morphologies can 
be promoted by different solid surfaces. A classic example of this is the aggregation of 
Aβ, a protein associated with Alzheimer’s disease, aggregating on mica [6] or graphite 
[7]. While Aβ forms oligomers that coalesce into protofibrils with a beaded morphology 
on mica, it forms extended, flat nano-ribbons on graphite that are epitaxially oriented. 
Like solid surfaces, lipid membrane can also alter the aggregation process. For most 
amyloid proteins, the formation of fibrils is accelerated in the presence of lipid 
membranes compared to bulk solution [8-10]. Amyloid-forming proteins can bind 
and/or insert into lipid membrane and accumulate within cellular or subcellular 
membranes [11, 12], accelerating the nucleation process. Lipid composition within a 
membrane can also influence the aggregation process [13]. 
HD is a progressive neurological disorder. Psychiatric manifestations, cognitive 
loss, and chorea [14] are the typical symptoms. Neuronal cell loss occurs mainly in the 
cerebral cortex and striatum with up to 30% of brain mass [15]. HD is inherited by a 
dominant genetic mutation in an autosomal fashion. The genetic mutation is abnormally 
long CAG-repeats in the huntingtin gene which encodes an extended polyglutamine 
(polyQ) stretch near the N-terminus of the huntingtin (htt) protein. In brain tissues, 
polyQ directly causes htt protein to aggregate into different types of aggregates, 
eventually forming cytoplasmic and nuclear inclusion bodies [16] which are the 
hallmarks of HD. Inclusion bodies are commonly thought to be the pathological agents 
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by potentially sequestering or incorporating some important proteins [17]. The age of 
onset and disease severity are tightly correlated with the length of polyQ with a 
threshold ~35 glutamines required for disease [18]. The presence of expanded polyQ 
promote the formation of fibrillary structures rich in ß-sheet content (amyloid fibril). 
But the assembly of mutant htt into mature amyloid fibril can adopt various aggregation 
pathways. There are several metastable intermediate aggregate species along the 
pathway such as oligomers and amorphous aggregates, which are associated with 
varying degrees of toxicity [19]. It has been suggested that the small diffusible 
aggregates like oligomer are more toxic and that the mature fibril are inert or potentially 
protective [20]. The most toxic pathologic species remain controversial. 
Htt aggregation adopts the nucleation-growth mechanisms. The nucleation event 
is critical to the initiation of aggregation; although, the event is a slow process and 
thermodynamically unfavorable. Once nucleated, aggregation proceeds by 
incorporating htt monomers into different aggregate species leading to the growth phase. 
For pure polyQ peptides, the nucleus is thought to be a monomer which undergoes a 
conformational change [21]. Once flanking sequences associated with htt are added to 
polyQ peptides, a critical tetramer nucleus has been observed [22, 23].  
Full length htt is more than 3000 amino acids long and it can be cleaved by several 
proteases. Although there are many htt N-terminal fragments, the exon1 has a 
potentially important role in HD. Exon1 fragment can be detected in transgenic mice 
expressing full length htt [24] and in HD patients [25] due to the aberrant cleavage of 
full length htt in polyQ length dependent manner [26]. In knock-in mouse model, 
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expression of exon1 with an expanded polyQ leads to a progressive neurological 
phenotype [16, 27]. 
Htt is a multifunctional protein and is present in mammals. Expression of htt is 
essential for brain development and neuronal survival [28]. In mouse model, knockout 
of htt gene is lethal [29]. Htt plays an important role in vesicle trafficking i.e. the 
transport of lipid vesicles (endocytic, synaptic or lysosomal), especially along 
microtubules [30-33]. In membrane fractions from brains, htt is detected [34]. Htt can 
localize to various subcellular compartments as its normal function [35]. Specifically, 
htt binds to ER reversibly and to mitochondria [36, 37]. Htt inclusion bodies incorporate 
multi-vesicular membrane into their surfaces [38, 39]. All of this implicates that htt 
intimately interacts with various lipid membranes. Although full length htt has multiple 
lipid binding sites [40], the highly conserved first 17 amino acid (Nt17) in the N terminus 
is thought to target lipid membranes. In the presence of lipid membranes, Nt17 has an 
induced α helix structure [41]. Furthermore the flank polyQ domain promotes the 
insertion of htt into lipid membrane [42]. Htt disrupts lipid bilayers in a polyQ length 
dependent manner [43].  
Cholesterol is a main component of biological lipid membranes, especially in 
neurons. Approximately 25% of the lipids content in neuronal membranes is cholesterol, 
and 70% of myelin sheaths is comprised of cholesterol [44]. All of this indicates that 
cholesterol plays an important role in brain tissues. Structurally, cholesterol influences 
membrane’s thickness and fluidity [45]. Functionally, the important property of 
electrical insulation for neuron cells is related to the cholesterol’s ability to limit ion 
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leakage through membrane [46]. Also, cholesterol affect neurotrophic factors, 
transmitter receptors and signal reduction that are specific to neuron cells [47]. 
Cholesterol does not cross the blood brain barrier, so all the cholesterol in the central 
nervous system is synthesized endogenously which is a complex process and can be 
affected by many factors. 
Altered cholesterol homeostasis is observed in cellular and animal models of HD, 
as well as in HD patient tissues [48-50]. Although cholesterol biosynthesis is reduced 
in HD, the specifics of altered cholesterol content remains controversial. A decrease in 
cholesterol content is reported [51-54] by numerous studies. An increase in cholesterol 
levels are also demonstrated by other reports [55-58]. Many of these discrepancies may 
be associated with methodology and model systems used to study cholesterol levels in 
HD. 
The role of htt aggregation in HD is well established; however, investigation of 
environmental factors which can influence the aggregation process is still important. 
Although the presence of lipid membrane can change htt aggregation, the role of lipid 
composition in modulating htt aggregation is poorly understood. The fact that 
cholesterol is important to neurons and the hemostasis of cholesterol in HD is altered 
indicates that cholesterol may play an important role in HD. Here, we characterize the 
interaction of htt exon1 fragments with total brain lipid extract (TBLE) lipid 






TBLE/PDA lipid vesicle protein 
binding assay: Conjugated 
polydiacetylene (PDA) is polymer 
which has a long conjugation network 
and exhibits chromatic properties. 
Experiencing surface pressure resulting 
in the perturbation of the PDA 
dependent side chains, PDA can have a 
rapid irreversible blue-red colorimetric 
transitions due to a subtle induced 
structural transition that shortens the 
effective conjugation network of the 
backbone of the polymer. Hydrophilic 
head group and hydrophobic tail that 
give the PDA lipidomimetic structure promotes lipid/PDA mixing and formation of 
biomimetic membrane assemblies. It has been shown that biological analytes primarily 
interacting with the lipid domains can still induce the blue-red transformations. 
Although the mechanism has not been fully elucidated, it’s been proposed that the 
interaction between analytes and lipid domains can influence the structure of PDA 
through the lipid/polymer interface. Compared to the moderate blue-red transformation 
generated by the deeper penetration into the hydrophobic core, the surface disturbance 
 
Figure 2 colorimetric sensing with TBLE/PDA 
vesicles. Structural transformation of PDA (blue) 




interacting with the lipid head group can induce more pronounce color transition, i.e. 
protein/lipid binding [59](Figure 2). Through the blue-red colorimetric change of the 
PDA/lipid vesicles aggregation of amyloid proteins to membrane can be studied [60-
63]. Furthermore, this transition can be quantified and obtained by determining the 
percentage colorimetric response (％CR), defined as [60, 62] 
 
%CR = [(PB0 - PBI)/PB0] × 100 
 
where PB is a red/blue ratio of absorbance (A) defined as Ablue/ (Ablue + Ared). Ablue is 
the “blue” component in the UV-vis spectrum (≈640 nm); Ared is the “red” 
component (≈500 nm), PB0 is the red/blue ratio of the control sample (before induction 
of color change), and PBI is the value obtained for the vesicle solution after addition of 
peptides.  
Atomic force microscopy: AFM is an important technique for imaging with nanoscale 
spatial resolution. Unlike the optical microscopy suffering from the spacial resolution 
limitations mainly due to the diffraction limit of light, a cantilever is used to interact 
directly with the sample to collect the sample surface information that is used to 
reconstruct the sample surface topography. In AFM, the cantilever is allowed to 
physically interact with the sample. A laser beam is projected into the sharp tip of the 
cantilever and reflected onto a photo detector to generate an optical lever. Through the 
optical lever, the vertical movement of the cantilever is amplified and monitored. In 
tapping mode AFM, the cantilever is harmonically driven near the resonance frequency. 
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When the cantilever interacts with the sample by intermittently making contact at the 
bottom of an oscillation cycle, the oscillation amplitude is changed to a tapping 
amplitude. By maintaining the tapping amplitude to a pre-determined value, or set-point, 
while raster scanning the probe across the surface, the sample topography and other 
properties can be characterized. Both height image and phase image can be obtained. 
In phase imaging, the shift in the phase of the oscillating probe tip with respect to the 
oscillating drive is mapped and provide information about the compositional contrast 
of the surface. In solution, local elasticity of lipid membrane can be mapped because of 
the sensitivity of phase-shifts to local elastic response [64]. Topographic information is 
indicated by the height image while phase image is sensitive to variations in 
composition, adhesion, friction, viscoelasticity as well as other factors [64]. In recent 
years, AFM has become a particularly useful technique in investigating disease related 
protein aggregation process, especially amyloid formation. Furthermore, tapping mode 
AFM can work in solution, providing the opportunity to monitor protein aggregation 
under physiologically-relevant conditions. From small oligomers to huge mature fibrils, 
aggregation species can be observed on surfaces such as lipid membranes [6, 7, 9, 10, 
43, 65, 66]. Continuously imaging the same surface area allows for tracking the fate of 





Purification of GST-htt-exon1 fusion proteins: Expression of GST-htt fusion 
proteins was accomplished by transfecting Escherichia coli with the appropriately 
designed plasmid (Figure 3). After growing an appropriate concentration of E.coli in 
LB broth, isopropyl β-D-thiogalactoside was added to induce the expression of the 
fusion protein at 30°C for 4h. The cells were pelleted by centrifugation. Protease 
inhibitor was added, and the cells were lysed by adding 0.5 mg/mL lysosome. Ultra-
sonication was used to further break the cells and release fusion protein. A GST affinity 
column was used to purify the lysate by liquid chromatography. Relevant fractions were 
collected, and SDS-PAGE electrophoresis was performed to verify the product and 
determine purity. Protein was concentrated by centrifugal filter after 48 hours of 
dialysis. Pre-existing aggregates were removed by high spin centrifuge at 20,000g for 
30min. Cleavage of the GST moiety was achieved by Factor Xa. Cleavage initiates 
aggregation. Prior to addition to any lipid membranes, fusion protein and Factor Xa 
were incubated on ice for 1 hour to generate enough cleaved htt protein for the assay.  
TBLE/PDA lipid vesicle protein binding assay: TBLE (Avanti Polar Lipids), 
diacetylene monomers 10,12-tricosadiynoic acid (GFS Chemicals, Columbus, OH) and 
 
Figure 3 scheme of fusion protein htt exon1 (Q51) there are 51 glutamine repeats (Q51) and 
there is a cleavage site (Factor Xa site) between GST and htt exon1 (Q51) 
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an appropriate amount of cholesterol was dissolved in a solution of 1:1 
chloroform/ethanol. The molar ratio of total lipid (TBLE + cholesterol) to PDA was 
2:3. Rotary evaporator was used to evaporate the solution, leaving a thin, dry film on 
the round bottled flask. 70 °C Tris-buffered saline (TBS) was added to the flask and 
sonicated at 100 W using a sonic dismembrator (FisherSci) to resuspend the mixture 
and generate TBLE/PDA vesicles. The suspension was stored in a beaker at 4 °C 
overnight to ensure self-assembly of vesicles. The diacetylene monomers were 
polymerized by irradiation at 254nm with 7 lumens for 10 minutes with stirring, 
resulting in a brilliant blue color. Htt-exon1(Q51) and polymerized TBLE/PDA was 
added into the wells of 96 well plate. As controls, TBS (negative control) and NaOH 
(pH 12) (positive control) were added into the wells containing htt-exon1(Q51). The 
final concentration of htt-exon1(Q51) was 20µM in each well. Each experiments were 
performed in triplicate in a 96-well format. The colorimetric response of each well was 
recorded over 16h using an Infinite M1000 Pro plate reader (TECAN, Switzerland) at 
room temperature measuring both the blue component (640nm) and the red component 
(500nm) of the spectrum. 
Preparation of supported TBLE bilayers for AFM experiments: TBLE (Avanti Polar 
Lipids) and cholesterol (Avanti Polar Lipids) were separately dissolved in chloroform 
(Fisher Scientific). Based on mass, 10%, 20% or 30% exogenous cholesterol was added 
to TBLE. The chloroform was then evaporated off to form a lipid film. These films 
were resuspended in PBS at a concentration of 0.5 mg/ml by vortexing and sonication. 
A series of 5 freeze-thaw cycles promoted the formation of bilayers and multilayer lipid 
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sheets. Bath sonication was then performed for 8 minutes to promote the formation of 
lipid vesicles from the lipid sheets. 35µL of the vesicle solution was injected into the 
AFM fluid cell and exposed to freshly cleaved mica. By fast continual AFM scanning, 
the cantilever aided in fusing the lipid vesicles into a supported lipid bilayer. 35µL of 
PBS was then injected into the fluid cell and sucked out three times to remove excess 
lipid vesicles. 
AFM imaging condition: In situ AFM experiments were performed with a Nanoscope 
V MultiMode scanning probe microscope (Bruker, Santa Barbara, CA) equipped with 
a sealable fluid cell and a closed-loop “vertical engage” J-scanner. Silicon cantilevers 
(VISTA probes) with a nominal spring constant of 0.1 N/m were used to capture images. 
Scan rates were set to ~1.95Hz with cantilever drive frequencies ranging from ~4 to 8 
kHz. The tapping amplitude was set at about 75% of free amplitude which was ~ 25nm. 
AFM images were processed with custom written scripts that use the Matlab image 





Enriching TBLE with cholesterol 
alters the extent of htt-exon1 
binding to lipid vesicles as 
determined by a TBLE/PDA 
binding assay: To verify that 
altering the lipid content of TBLE 
would modulate the interaction of 
full-length htt-exon1 with lipids, 
we performed a TBLE/PDA 
vesicle lipid binding assay (Figure 
4). Four experiments were 
performed with TBLE/PDA vesicles enriched with 0% (pure TBLE), 10%, 20%, 30% 
exogenous cholesterol by mass. The vesicles were exposed to 20µM htt-exon1 (Q51), 
and the colorimetric response was continuously measured for 16 hours. For every 
experiment, once the vesicles are exposed to htt-exon1 (Q51) an initial steady increase 
in %CR starts. With time, the %CR finally levels off to a stationary state. With 
increasing amounts of cholesterol, the initial increase in %CR was less steep, indicating 
the binding of htt-exon1 (Q51) to the vesicles was inhibited. Also, as the exogenous 
cholesterol content was enriched from 0% to 30%, the final stationary state %CR 
decreased, which indicates that the overall protein lipid binding was reduced. Still, there 
was significant interaction between htt-exon1 (Q51) and lipid vesicles even for 
 
Figure 4 TBLE/PDA binding assay The percent 
colorimetric response (%CR) of TBLE/PDA vesicles 
containing various amounts of cholesterol upon 
exposure to htt-exon1(51Q) plotted as a function of 
time. The highlighted area indicates the timeframe 
accessible with AFM experiments described later. 
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TBLE/PDA vesicles containing 30% exogenous cholesterol.  
Cholesterol modulates the morphological and mechanical changes in lipid bilayers 
associated with exposure to htt-exon1 (Q51): To investigate the influence of cholesterol 
on the aggregation of htt on lipid membranes, supported TBLE bilayers containing 
various amounts of cholesterol were exposed to htt-exon1 (51Q) and continuously 
imaged using in situ AFM, allowing for the direct tracking of protein aggregation on 
the bilayer. Supported lipid bilayer can be formed by fusion of lipid vesicles on the 
hydrophilic surface of mica. There are various kinds of forces between the lipid bilayer 
and mica which stabilized the bilayer near the surface. However, there is still a gap 
between the mica and the bottom leaflet of the bilayer [67]. The supported lipid bilayer 
still retains many free membrane properties i.e. lateral fluidity [67]. As a result, 
supported lipid bilayers are an appropriate model surfaces to study the interaction of 
amyloid-forming proteins with lipid membranes [9, 10, 43, 65, 66]. Height images 
(surface topography) and phase images were obtained simultaneously.  
For every experiments, only a small size lipid bilayer (10 x 10 µm) was 
continuously monitored by AFM. However, a large area (40 x 40 µm in size) 
surrounding this small patch of lipid was verified before exposure to htt-exon1 (51Q). 
The unperturbed bilayers typically had a RMS roughness value less than 0.2 nm. First, 
it was confirmed that stable, supported TBLE enriched with different amounts of 
exogenous cholesterol could form smooth, structurally stable bilayers. Bilayers indeed 
formed, and there was no indication of distinct lipid domains or structural instability in 
either AFM height or phase images for several hours (Figure 5).  
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While only a 10 x 10 µm patch was continuously monitored in the AFM 
experiments, the scan area was intermittently off-set to image an area of the larger 
bilayer that had not been previously imaged. This was done as a control to make sure 
that the scanning process was not influencing the aggregation process.  
For all the experiments, the supported lipid bilayers with varying amounts of added 
cholesterol were exposed to freshly prepared aliquots of htt-exon1 (Q51) at a final 
protein concentration of 20 µM in the fluid cell. When pure TBLE was exposed to 20 
µM solutions of htt-exon1 (Q51), large areas of the bilayer were disrupted extensively 
and immediately; although, some small regions appeared unaffected (Figure 6). In the 
disrupted regions, RMS surface roughness increased, and discrete aggregates 
accumulated. With time, the disrupted areas expanded and became even rougher. The 
aggregates also increased in number and size.  
    In the AFM phase images, there was distinct contrast between the affected 
area and unperturbed regions, and this contrast remained consistent during the 
120minutes observation. This suggests that there are mechanical differences between 
 
Figure 5 Images of TBLE containing different amount of cholesterol. After several hours 
scanning, no nanoscale defects are observed in height and phase images. 
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these different regions of the bilayer. This observation is consistent with previous 
reports that similar morphological changes in bilayers exposed to htt were associated a 
decreased compression modulus of the membrane [65, 68]. 
 
Of note, the aggregates observed on pure TBLE bilayers were globular in shape. These 
oligomers were fairly stable on the membrane, as they could be identified in 
consecutive images. Htt-exon1 (Q51) at similar concentrations aggregates into fibrils 
in the absence of lipid within an hour; however, there were no fibrils observed during 
 
Figure 6 Sequential AFM height and phase images taken in solution of supported TBLE bilayers 
exposed to htt-exon1 (51Q). Blue arrows indicate oligomer-like structures. (B) AFM height 
image taken after 120 min demonstrating the rough, grainy morphological changes induced in a 
pure TBLE bilayer by htt-exon1 (51Q). Blue line corresponds to the height profile presented 
directly below the image. 
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the 2h time course of these experiments. This suggests that the TBLE bilayers can either 
stabilize aggregate intermediates or promote the formation of aggregates off the regular 
pathway to fibrils. 
Morphologic changes were observed on TBLE bilayers containing 10% 
exogenous cholesterol upon exposure to 20 µM htt-exon1 (Q51) that were distinct to 
those occurring on pure TBLE systems. Initially, compared to the extensive disruption 
on pure TBLE, the disrupted regions were small and more disperse on the bilayer 
(Figure 7). Slight increases in height were initially detected in these small domains 
 
Figure 7 (A) Sequential AFM height and phase images taken in solution of supported TBLE 
bilayers containing 10% exogenously added cholesterol exposed to htt-exon1 (51Q). (B) AFM 
height image taken after 120 min demonstrating the smooth morphological changes induced in 
a TBLE + 10% cholesterol bilayer by htt-exon1 (51Q). Blue line corresponds to the height 
profile presented directly below the image. 
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compared to the unperturbed regions. Mechanical changes were also observed on the 
lipid bilayer, as indicated by phase images. With time, these domains grew in area and 
pronounced increase in their height were observed. Interestingly, as the domain grew, 
the phase contrast decreased, suggesting that the perturbed and unperturbed regions of 
the bilayer have similar elastic properties.  
In the pure TBLE bilayer, the aggregates were grainy in appearance, but the 
domains in TBLE with 10% cholesterol were plateau-like with a smoother appearance. 
While there were a few globular aggregates associated with these plateau-like domains, 
 
Figure 8 (A) Sequential AFM height and phase images taken in solution of supported TBLE 
bilayers containing 20% exogenously added cholesterol exposed to htt-exon1 (51Q). (B) 
Sequential AFM height and phase images taken in solution of supported TBLE bilayers 
containing 30% exogenously added cholesterol exposed to htt-exon1 (51Q). 
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there was an obvious decrease in the number of such aggregates. The height of the 
smoother domain that developed on the TBLE containing exogenous 10% cholesterol 
gradually grew from ~1nm to ~4 nm above the regions of unaffected regions. 
Similar morphological 
changes in membrane topography 
in TBLE bilayers containing added 
10% cholesterol were observed in 
TBLE bilayers containing 20% and 
30% exogenous cholesterol 
(Figure 8). Specifically, clear 
phase contrast was detected at 
initial exposure, and small domains 
slightly higher than the unaffected 
bilayer were observed. With time, 
these domains grew in size and formed a smooth plateau-like domain. The initial 
distinct contrast disappeared with the development of the domains in the AFM phase 
images. As the cholesterol content increased, surface area disrupted by exposure to htt-
exon1 (Q51) was reduced. Also, the formation of the smooth domain was slowed. The 
percentage of surface with altered morphology was used to quantify the interaction of 
htt-exon1 (Q51) with the supported lipid bilayers. As cholesterol content increased, the 
extent of bilayer disruption decreased in a consistent manner with the PDA binding 
assay (Figure 9). 
 
Figure 9 The percent area of disrupted bilayer 
morphology associated with exposure of lipid 
bilayers containing various amounts of cholesterol 
to htt-exon1(51Q) presented as a function of time. 





Here, we investigated the role of cholesterol on modulating the interaction 
between htt and lipid membranes. Several findings have been reported. The binding of 
htt-exon1 (Q51) onto lipid membrane was reduce with the increase of cholesterol 
content in membranes. But there was still appreciable binding of htt-exon1 (Q51) to 
membranes even with up to 30% exogenously added cholesterol. Morphological and 
mechanical change also have been reported. A significant population of globular 
aggregates were formed when pure TBLE bilayers was exposed to htt-exon1 (Q51). 
The disrupted regions of the bilayer were associated with distinct contrast in AFM 
images, indicating altered elastic properties. Compared to grainy disrupted morphology 
in pure TBLE bilayers, discrete, thicker domain developed on the bilayer surface with 
relatively few globular htt aggregates when cholesterol content was increased. 
Furthermore, the extent of bilayer disruption was significantly reduced with increasing 
cholesterol content in lipid bilayers upon exposure to htt-exon1 (Q51). 
The transcription of cholesterogenic genes is deregulated in HD. In clonal striatal-
derived cells that overexpress mutant htt, mRNA levels of import genes associated with 
cholesterol biosynthesis seem to be reduced [69]. Sterol regulatory element binding 
protein can promote transcription of many cholesterol biosynthesis genes, and its 
activity is reduced in cell and mouse models of HD. Furthermore, the activity of the 
synthetic enzyme HMGCoAR, which is a crucial enzyme in cholesterol biosynthesis 
and the level of cholesterol precursors (such as lanosterol and lathosterol), are reduced 
from four different HD rodent models [52, 70]. Although the disruption of cholesterol 
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homeostasis in human is generally accepted, accumulation and depletion of cholesterol 
are both reported [51-58]. It has been suggested that the limitation on the assays to 
quantify cholesterol levels may be responsible for the diverging results [71]. An 
increase in cholesterol content, as measured by filipin staining in YAC72 mice, was 
observed [72], but the application mass spectrometry techniques to assess absolute 
levels of cholesterol and its metabolites indicates a decrease in cholesterol content in 
YAC72 mice [70]. A potential decrease in cholesterol content may originate from the 
disruption of cholesterol biosynthesis [52, 53, 56, 70]. It is suggested that the potential 
accumulation of cholesterol in intracellular spaces derives from the inhibition of 
clathrin-independent endocytosis by mutant htt [55]. Intracellular trafficking of 
cholesterol is impaired and cholesterol accumulates in cells. The accumulation of 
cholesterol in HD cellular and animal models, as in HD human brains, may contribute 
to NMDA-mediated excitotoxicity [57]. These finding are limited to cell and animal 
modes or postmortem tissues and investigations in HD patients are needed. Despite the 
conflicting reports on cholesterol levels in HD, it is demonstrated that cholesterol can 
modulate the binding of htt to lipid membrane and aggregate formation. Also, Langmuir 
trough and vesicle popping experiments performed in the lab of a collaborator, Shelli 
L. Frey, indicate that cholesterol reduces the insertion of htt into lipid membranes and 
completely prevents htt-induced permeability of lipid membranes. These observations 
justify further studies needed to resolve the controversy about how cholesterol 
homeostasis is altered in HD. 
Lipid rafts are special membrane domains enriched in lipid cholesterol and 
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proteins. In HdhQ111 knock in mouse model, cholesterol accumulates in membrane and 
membrane rafts increase when exposed to mutant htt [57]. Here, distinct domains were 
observed when mutant htt was exposed to bilayers with excess cholesterol that were 
reminiscent in some ways to lipid rafts. It is reasonable to speculate that these plateau-
like domains were enriched in both htt and cholesterol. Due to the incorporation of htt 
protein into the domains, theses domains are much thicker than normally observed lipid 
raft domains in pure lipid bilayer systems [73, 74]. 
The initial affinity of htt to bind lipid bilayer is impeded by increasing cholesterol 
content in lipid membrane. The insertion of htt into lipid monolayers was also inhibited, 
as shown by collaborative studies with Shelli L. Frey. A condensation or a stiffening 
effect of adding cholesterol to the TBLE system may be a reason for these observations. 
Even after the htt binding to or insertion into the lipid membrane, bilayer morphology 
and aggregation process also are dependent on the cholesterol content.  
Various aggregate species with different structures can be formed from htt. The 
polyQ domain in htt can itself adopt variant conformations as a monomer [75] that can 
lead to a variety of different aggregates [76]. Distinct monomeric conformation may 
play different roles in HD. For example, the monoclonal antibody 3B5H10 recognizes 
monomeric species of polyQ that predicts neuronal death in cell culture [77]. Various 
aggregates species are associated with varying levels of toxicity. Therefore, it is 
plausible that a subset of the aggregate conformers has a prominent role in mediating 
pathogenesis in HD. Since the aggregation process can be influenced by a variety of 
external factors, it is important to determine how the protein environment promotes the 
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formation and stabilization of disease relevant htt conformations. Lipid membranes 
represent an important physiologically-relevant factor. The interaction of htt with 
membrane surfaces results in altered mechanical integrity of membranes leading to their 
dysfunction and stabilization or promotion of specific aggregate species [43, 65, 78]. It 
has been found that lipid membranes facilitate the formation of distinct aggregate 
species of htt fragments depending on the domains flanking the polyQ stretch [65]. 
Here, we demonstrate the composition of lipid membranes can modulate the 
aggregation of htt. Specifically, the cholesterol content in lipid bilayer promotes the 
formation of distinct aggregation species on lipid membranes.  
Protein aggregation can disrupt membrane integrity and that is proposed as a 
potential mechanism associated with several neurodegenerative diseases. Induced 
mechanical changes in lipid membrane could underlie the membrane dysfunction 
observed in animal models of HD [4]. Here, it is demonstrated that the bilayer 
containing exogenously added cholesterol facilitates the formation of distinct domain 
on membrane surfaces upon exposure to htt. Interestingly, these results correlate with 
calcium dye leakage experiments which indicate that even a modest increase in 
cholesterol can dramatically alters the susceptibility of TBLE membranes to 
permeabilization. As the domains observed on membranes containing extra cholesterol 
upon exposure to htt have similar elastic properties compared to the unaltered bilayers, 
they may be less susceptible to leakage. These mechanical changes may result in a 
protective effect of additional cholesterol on the integrity of lipid membranes. 
Interestingly, the development of the discrete globular htt aggregates on pure TBLE 
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surface exposed to htt-exon1 (Q51) correlates with increased bilayer roughness and 
dramatic increases in a lipid bilayer’s susceptibility to permeabilization.  
CONCLUSION 
As a main component of lipid membrane, cholesterol plays a significant role in 
modulating the interaction of htt with lipid membrane. With increasing cholesterol 
content in lipid bilayer, the binding affinity decreases. Morphologically, distinct 
aggregates are formed on the lipid bilayer. Mechanically, with the addition of 
cholesterol in lipid bilayer, the disrupted area and unaffected area have similar 
mechanical properties, which may be responsible for the protective ability to reduce 
membrane integrity disruption.  
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